Overview of the drug development pipeline for retinal vein occlusion
It has been observed that retinal vein occlusion RVO occurs due to a blockage in a retinal vein, which causes blood to flow from the retina back to the heart, leading to the blockage of fluid from blood vessels. It increases pressure in the eye, which causes bleeding and swelling and can harm vision. RVO is of basically two types including central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). CRVO arises when there is a blockage in a main retinal vein and BRVO arises when there is a blockage in one of the smaller branch veins. Several treatments for RVO include intravitreal therapy, laser therapy to reduce swelling caused by fluid leakage, drug injections to reduce inflammation, and surgery. Consequently, the rising incidences of retinal vein occlusion is expected to boost the drug development for retinal vein occlusion during the forthcoming years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for retinal vein occlusion. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Adverum
- Aerpio
- Annexin Pharmaceuticals
- Clearside Biomedical
- Gene Signal
Therapeutic assessment of the drug development pipeline for retinal vein occlusion by route of administration
- Intravitreal
- Topical
- IV
- Subcutaneous
The intravitreal route of administration (ROA) involves the application of the drug directly in the eye, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for retinal vein occlusion by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for retinal vein occlusion are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for retinal vein occlusion?
- What are the companies that are currently involved in the development of drug molecules for retinal vein occlusion?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX